LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
31 funds hold it · Insiders net selling
Net selling: insiders sold $347.7M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Nov 4, 2026
Financial period
Q3 2026
Earnings per share
$6.34 expected
Revenue
$781.1M expected
Estimates as of Nov 10, 2026
EPS expected
$4.04 to $7.01
Revenue expected
13 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Nov 4, 2026 | $5.71est. $6.34 | -9.97%miss | $832.5Mest. $781.1M+6.57% | +4.1%from $799.5M |
| Jun 30, 2026Reported Aug 5, 2026 | $7.27est. $7.03 | +3.47%beat | $783.3Mest. $804.6M-2.65% | -1.9%from $798.6M |
| Mar 31, 2026Reported May 6, 2026 | $5.82est. $7.04 | -17.38%miss | $781.5MSEC filing | -1.6%from $794.4M |
| Dec 31, 2025Reported Feb 25, 2026 | $7.70est. $7.24 | +6.35%beat | $790.2MAlpha Vantage | +7.4%from $735.9M |
| Sep 30, 2025Reported Oct 29, 2025 | $7.16est. $6.96 | +2.87%beat | $799.5MSEC filing | +6.8%from $748.9M |
| Jun 30, 2025Reported Jul 30, 2025 | Not on file | No estimate | $798.6MSEC filing | +11.7%from $714.9M |
| Mar 31, 2025Reported Apr 30, 2025 | $6.63est. $6.54 | +1.38%beat | $794.4MSEC filing | +17.2%from $677.7M |
| Dec 31, 2024Reported Feb 26, 2025 | $6.19est. $6.27 | -1.23%miss | $735.9MAlpha Vantage | +19.7%from $614.7M |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $790.2M | $781.5M | $783.3M | $832.5M |
| Cost of what it sold | $103.4M | $133.4M | $99.5M | $99.1M |
| Gross profit | $686.8M | $648.1M | $683.8M | $733.4M |
| What it spent | ||||
| Research and development | $139.5M | $138.2M | $146.3M | $279.2M |
| Sales and admin | $157.1M | $155.4M | $137.9M | $146.4M |
| Other operating costs | $32.7M | $28.7M | $68.8M | — |
| Total operating expenses | $329.3M | $322.3M | $353.0M | $425.6M |
| What was left | ||||
| Operating profit | $357.5M | $325.8M | $330.8M | $307.8M |
| Interest on debt | $3.1M | $3.0M | $2.9M | $2.9M |
| Profit before tax | $444.0M | $318.3M | $372.7M | $372.8M |
| Tax | $79.7M | $43.4M | $39.7M | $114.2M |
| Net profit | $364.3M | $274.9M | $333.0M | $258.6M |
| EBITDA | $469.9M | $343.9M | $399.8M | $368.4M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
After exercising options, United Therapeutics (UTHR) director sells 1,210 shares at $580 each.
Leans bearishNov 10Under a pre-arranged plan, United Therapeutics (UTHR) CEO family trusts sold 1,614 shares.
Leans bearishNov 10Rochester now has a xenotransplant facility in its backyard. Experts say this field is primed for progress
BullishNov 10After exercising options at $117.76 a share, United Therapeutics (UTHR) CEO trust sells 9,500 shares.
NeutralNov 9Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 6 November
NeutralNov 9H.C. Wainwright resumed coverage on United Therapeutics with a new price target
BullishNov 9United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
Leans bullishNov 9Martine Rothblatt, United Therapeutics CEO, sells $4.3M in shares By Investing.com
NeutralNov 734 macro signals shaping UTHR right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
